EP1993578A1 - Mittel zur behandlung von tinnitus - Google Patents
Mittel zur behandlung von tinnitusInfo
- Publication number
- EP1993578A1 EP1993578A1 EP07711962A EP07711962A EP1993578A1 EP 1993578 A1 EP1993578 A1 EP 1993578A1 EP 07711962 A EP07711962 A EP 07711962A EP 07711962 A EP07711962 A EP 07711962A EP 1993578 A1 EP1993578 A1 EP 1993578A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- vitamin
- use according
- magnesium
- tinnitus
- blueberry extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 208000009205 Tinnitus Diseases 0.000 title claims abstract description 37
- 231100000886 tinnitus Toxicity 0.000 title claims abstract description 25
- 238000011282 treatment Methods 0.000 title claims description 11
- 239000000126 substance Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 claims abstract description 21
- 235000019216 blueberry extract Nutrition 0.000 claims abstract description 15
- 229940055416 blueberry extract Drugs 0.000 claims abstract description 15
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 7
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 18
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 18
- 239000000284 extract Substances 0.000 claims description 13
- 239000000395 magnesium oxide Substances 0.000 claims description 10
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 10
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 9
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 9
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 9
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 9
- 229930003471 Vitamin B2 Natural products 0.000 claims description 9
- 235000019152 folic acid Nutrition 0.000 claims description 9
- 239000011724 folic acid Substances 0.000 claims description 9
- 229960000304 folic acid Drugs 0.000 claims description 9
- 239000011777 magnesium Substances 0.000 claims description 9
- 229910052749 magnesium Inorganic materials 0.000 claims description 9
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 9
- 229960002477 riboflavin Drugs 0.000 claims description 9
- 235000019164 vitamin B2 Nutrition 0.000 claims description 9
- 239000011716 vitamin B2 Substances 0.000 claims description 9
- 235000019158 vitamin B6 Nutrition 0.000 claims description 9
- 239000011726 vitamin B6 Substances 0.000 claims description 9
- 229940011671 vitamin b6 Drugs 0.000 claims description 9
- 235000017537 Vaccinium myrtillus Nutrition 0.000 claims description 8
- 229930003451 Vitamin B1 Natural products 0.000 claims description 8
- 229930003779 Vitamin B12 Natural products 0.000 claims description 8
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims description 8
- 235000008524 evening primrose extract Nutrition 0.000 claims description 8
- 229940089020 evening primrose oil Drugs 0.000 claims description 8
- 239000010475 evening primrose oil Substances 0.000 claims description 8
- 229960003495 thiamine Drugs 0.000 claims description 8
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 8
- 235000010374 vitamin B1 Nutrition 0.000 claims description 8
- 239000011691 vitamin B1 Substances 0.000 claims description 8
- 235000019163 vitamin B12 Nutrition 0.000 claims description 8
- 239000011715 vitamin B12 Substances 0.000 claims description 8
- 235000003095 Vaccinium corymbosum Nutrition 0.000 claims description 6
- 235000021014 blueberries Nutrition 0.000 claims description 6
- 239000007903 gelatin capsule Substances 0.000 claims description 6
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 6
- 239000007901 soft capsule Substances 0.000 claims description 6
- 239000003963 antioxidant agent Substances 0.000 claims description 4
- 235000006708 antioxidants Nutrition 0.000 claims description 4
- 239000011785 micronutrient Substances 0.000 claims description 4
- 235000013369 micronutrients Nutrition 0.000 claims description 4
- 238000011321 prophylaxis Methods 0.000 claims description 3
- 239000012141 concentrate Substances 0.000 claims description 2
- 229960000869 magnesium oxide Drugs 0.000 claims description 2
- 235000012245 magnesium oxide Nutrition 0.000 claims description 2
- 240000000851 Vaccinium corymbosum Species 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 description 13
- 239000003795 chemical substances by application Substances 0.000 description 8
- 244000078534 Vaccinium myrtillus Species 0.000 description 7
- 239000003814 drug Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 3
- 230000000378 dietary effect Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 206010011878 Deafness Diseases 0.000 description 2
- 229930014669 anthocyanidin Natural products 0.000 description 2
- 235000008758 anthocyanidins Nutrition 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- NWKFECICNXDNOQ-UHFFFAOYSA-N flavylium Chemical compound C1=CC=CC=C1C1=CC=C(C=CC=C2)C2=[O+]1 NWKFECICNXDNOQ-UHFFFAOYSA-N 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 230000010370 hearing loss Effects 0.000 description 2
- 231100000888 hearing loss Toxicity 0.000 description 2
- 208000016354 hearing loss disease Diseases 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 235000002918 Fraxinus excelsior Nutrition 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000001140 Night Blindness Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 206010046996 Varicose vein Diseases 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000002956 ash Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 229940087430 biaxin Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 1
- 230000001904 diabetogenic effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000021022 fresh fruits Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 239000012674 herbal formulation Substances 0.000 description 1
- 239000008173 hydrogenated soybean oil Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 235000021579 juice concentrates Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000002803 maceration Methods 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000000051 music therapy Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000009516 primary packaging Methods 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000002594 sorbent Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 206010041569 spinal fracture Diseases 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 208000027185 varicose disease Diseases 0.000 description 1
- 229940045999 vitamin b 12 Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
Definitions
- the invention relates to an agent for the treatment of tinnitus for oral administration, which contains blueberry extract, as well as antioxidants and micronutrients selected from magnesium oxide, vitamin B1, vitamin B2, vitamin B6, vitamin B 12, evening primrose oil and folic acid.
- blueberries as fresh fruits or (dry) extract
- circulatory disorders such as varices, hemorrhoids, diarrhea and a number of eye diseases such as cataracts, diabetogenic retinopathy, glaucoma, macular degeneration and night blindness as well as overuse of the eyes ( Computer) is widely used.
- Tinnitus is a dysfunction of the hearing system that can take on a variety of levels and structures, although there is no sound knowledge of the pathology of tinnitus.
- Tinnitus aurium (Latin for "the ringing of the ears"), or tinnitus for short, refers to a symptom in which the person perceives sounds that have no external source perceptible to other persons
- secondary symptoms such as sleep and concentration disorders, anxiety neurosis and depression, and often a normal lifestyle is limited or even impossible, and patients can become incapacitated for work or work.
- Patients suicidal As a cause of disease a multifactorial event is assumed. However, since there is no reliable knowledge about the pathophysiological basis of tinnitus, targeted rational drug therapy is not possible.
- the present invention accordingly provides a new, highly effective, purely natural drug or dietetic which is suitable for the prophylaxis and treatment of tinnitus / hearing loss.
- the medicaments according to the invention are natural, purely herbal formulations which are also well accepted and tolerated by patients who oppose allopathy.
- Blueberry extract according to the invention means a dry extract of the berries of Vaccinium myrtillus, i. the European blueberry, which is also called “Büberry” in Anglo-Saxon usage.
- a particularly preferred dry extract according to the invention is standardized to at least 25% anthocyanosides.
- a typical extract used according to the invention contains up to 4.5% water, up to 5% mineral parts (Sulfuric ashes), up to 5% free anthocyanidins and
- Such a Extract is commercially available eg as "BHberry Purified Dry Extract.”
- the dry extract can be prepared in a conventional manner from liquid drug extracts, for example by percolation, maceration, Soxhletmaschine, digestion in particular according to pharmacopoeia (eg Bonati A, J. Ethnopharmacol. 1991, April; 32 (1-3): 195-7)
- the blueberry extract used according to the invention can be prepared as shown briefly below.
- Fresh blueberries are squeezed to obtain a blueberry juice concentrate, which is then subjected to ultrafiltration and ethanol extraction or aqueous-alcoholic extraction.
- the resulting extract is concentrated in vacuo to a paste and dried to a powder, which is then ground to give the blueberry dry extract.
- a preferred formulation according to the invention contains per dosage unit, such as tablet or capsule:
- blueberry extract 50 to 500 mg of blueberry extract, 10 to 200 mg of magnesium (as magnesium oxide), 0.2 to 5 mg of vitamin B1, 0.2 to 5 mg of vitamin B2, 0.2 to 5 mg of vitamin B6, and 0.1 to 1 ⁇ g Vitamin B12.
- folic acid (0.01-10 mg) and evening primrose oil (10-100 mg).
- Vitamin B12 0.1 - 1 ⁇ g
- Vitamin B1 0.312 mg
- Vitamin B2 0.625 mg
- Vitamin B6 0.396 mg
- Vitamin B12 0.225 ⁇ g
- the dietetic agents or pharmaceutical agents according to the invention may also contain pharmaceutical formulation adjuvants such as fillers (carriers), e.g. Soybean oil or partially hydrogenated soybean oil, beeswax, butterfat and lecithin in soft gelatin capsules, disintegrants, binders, flow control agents, lubricants, emulsifiers, solvents or sorbents.
- carriers e.g. Soybean oil or partially hydrogenated soybean oil, beeswax, butterfat and lecithin in soft gelatin capsules
- disintegrants e.g. Soybean oil or partially hydrogenated soybean oil
- binders e.g. Soybean oil or partially hydrogenated soybean oil
- flow control agents e.g., lubricants, emulsifiers, solvents or sorbents.
- the dietetic agents or pharmaceutical agents according to the invention may be formulated in any dosage form suitable for oral administration by methods customary in the art, preferably solid dosage forms for oral administration such as tablets, hard gelatin capsules and soft gelatin capsules. Very particularly preferred are soft gelatin capsules. Oval soft capsules of sizes 2 to 20 minim and oblong soft capsules of sizes 6 to 22 minim, in particular oval soft capsules of size 10 minim, are preferred according to the invention. It is also particularly preferred in this case if the dosage form is present in special primary packaging means such as blister packs or blister packs, ie blistered. As can be seen from the results presented below, very significant treatment successes in the treatment of tinnitus could be achieved with the composition according to the invention, containing biaxin extract in combination with certain antioxidants and micronutrients.
- the patient has been suffering from ear noises for about 2-3 years. It usually perceives the ear noises on the left side as a noise. According to her information, she was therefore not at the doctor, she also took no medication in this regard. The sounds do not affect her daily life. Only before falling asleep, they were perceived as unpleasant.
- the patient started taking the composition according to the invention about 1 to 4 years ago (about mid-2005) and takes, partly irregularly, 2 capsules in the morning and 2 capsules in the evening. In case of migraine she adheres to the recommended intake described in the package insert.
- the patient has been suffering from tinnitus since 1993, who was diagnosed by an ear, nose and throat method and other methods by an ENT specialist. She perceives the tinnitus as whistling in the left ear. She does not take any medications in this regard, other therapeutic measures were not carried out with her.
- the patient is not restricted in her daily routine by the tinnitus, she indicates the strength of the sounds as "mediocre”. The patient takes for about 1/2 years regularly morning 3 Kapsein the inventive composition.
- the patient has had ear noises on both sides since 1997 and perceives them as whistles. She describes that the sounds occurred after a vertebral fracture and dental problems. A tinnitus diagnosis was not performed. The patient has performed no other therapeutic measures against tinnitus except a light music therapy. The ear noises were described as loud and thus disturbing. Due to the noise, the patient was partially restricted in her normal daily routine. She felt the sounds that affected her sleep, especially at night as very bad. The ear noises also made the patient appear more irritated to the family.
- the patient suffers from tinnitus as a result of a hearing loss since November 2005.
- the tinnitus was diagnosed by a naturopath.
- the patient perceived the ear noises as loud whistling and noise mostly on the right side.
- the noises did not cause any damage.
- the patient was extremely disturbed by the sounds at night, especially since she could not relax and could not fall asleep.
- the implementation of therapeutic measures such as acupuncture and massage and the use of tinnitus-matched globules were unsuccessful.
- the patient started taking the composition according to the invention in July 2006, since September 2006 she regularly takes 3 capsules in the morning and 3 capsules in the evening. From October 2006 she switched to the dose 2 capsules in the morning and 2 capsules in the evening.
- the ear noises which are z. existed for years, disappeared completely in 3 out of 4 patients. In one patient, the noise has improved significantly and the ear pressure is completely gone.
- Each of the patients has confirmed that the disappearance or amelioration of the ear noises is clearly due to the intake of the composition according to the invention.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Packages (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102006011922A DE102006011922A1 (de) | 2006-03-15 | 2006-03-15 | Mittel zur Behandlung von Tinnitus |
PCT/EP2007/002294 WO2007104566A1 (de) | 2006-03-15 | 2007-03-15 | Mittel zur behandlung von tinnitus |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1993578A1 true EP1993578A1 (de) | 2008-11-26 |
Family
ID=38229816
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP07711962A Ceased EP1993578A1 (de) | 2006-03-15 | 2007-03-15 | Mittel zur behandlung von tinnitus |
Country Status (9)
Country | Link |
---|---|
US (2) | US20090220592A1 (de) |
EP (1) | EP1993578A1 (de) |
JP (1) | JP2009529559A (de) |
AU (1) | AU2007224668A1 (de) |
CA (1) | CA2646528A1 (de) |
DE (1) | DE102006011922A1 (de) |
EA (1) | EA013457B1 (de) |
IL (1) | IL194066A0 (de) |
WO (1) | WO2007104566A1 (de) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201010691A (en) * | 2008-06-12 | 2010-03-16 | Merz Pharma Gmbh & Co Kgaa | 1-amino-alkylcyclohexane derivatives for the treatment of sleep disorders |
CA3094903A1 (en) * | 2018-03-23 | 2019-09-26 | Vanessa Research, Inc. | Compositions and methods for treating diarrheal diseases |
KR102175201B1 (ko) * | 2019-09-06 | 2020-11-06 | (주)아이엠디팜 | 빌베리 추출물을 유효성분으로 함유하는 감각신경성 난청 예방 또는 치료용 조성물 |
EP4299059A1 (de) | 2022-07-01 | 2024-01-03 | Labelic Analysis, S.L. | Zusammensetzung zur behandlung von tinnitus |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020061870A1 (en) * | 2000-01-27 | 2002-05-23 | Pearson Don C. | Dosage forms useful for modifying conditions and functions associated with hearing loss and/or tinnitus |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6103756A (en) * | 1999-08-11 | 2000-08-15 | Vitacost Inc. | Ocular orally ingested composition for prevention and treatment of individuals |
JP2002308752A (ja) * | 2001-04-06 | 2002-10-23 | Nikko Chemical Co Ltd | 皮膚外用剤 |
DE202004004618U1 (de) * | 2004-03-24 | 2004-05-19 | Aiones The Brainpower Company | Blaubeerextrakt |
WO2005092330A1 (de) * | 2004-03-24 | 2005-10-06 | Aiones The Brainpower Company | Arzneimittel oder diätetikum zur oralen verabreichung enthaltend blaubeerextrakt sowie antioxidatien und mikronährstoffe |
JP2005306882A (ja) * | 2005-06-08 | 2005-11-04 | Alan Smith Richard | 感情的不安定の治療のための医薬の製造に有用な組成物 |
-
2006
- 2006-03-15 DE DE102006011922A patent/DE102006011922A1/de not_active Withdrawn
-
2007
- 2007-03-15 WO PCT/EP2007/002294 patent/WO2007104566A1/de active Application Filing
- 2007-03-15 JP JP2008558724A patent/JP2009529559A/ja active Pending
- 2007-03-15 EP EP07711962A patent/EP1993578A1/de not_active Ceased
- 2007-03-15 AU AU2007224668A patent/AU2007224668A1/en not_active Abandoned
- 2007-03-15 CA CA002646528A patent/CA2646528A1/en not_active Abandoned
- 2007-03-15 US US12/282,691 patent/US20090220592A1/en not_active Abandoned
- 2007-03-15 EA EA200801890A patent/EA013457B1/ru not_active IP Right Cessation
-
2008
- 2008-09-14 IL IL194066A patent/IL194066A0/en unknown
-
2011
- 2011-07-21 US US13/188,180 patent/US20110280972A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020061870A1 (en) * | 2000-01-27 | 2002-05-23 | Pearson Don C. | Dosage forms useful for modifying conditions and functions associated with hearing loss and/or tinnitus |
Non-Patent Citations (4)
Title |
---|
FRANZ M. ET AL: "Tinnitus als soziale Infektion?", PSYCHOTHERAPEUT, vol. 50, no. 5, 1 September 2005 (2005-09-01), pages 318 - 327, XP019334085 * |
See also references of WO2007104566A1 * |
SEIDMAN M D ET AL: "ALTERNATIVE MEDICATIONS AND OTHER TREATMENTS FOR TIMMITUS: FACTS FROM FICTION", OTOLARYNGOLOGIC CLINICS OF NORTH AME, ELSEVIER, USA, vol. 36, no. 2, 1 April 2003 (2003-04-01), pages 359 - 381, XP009043380, ISSN: 0030-6665, DOI: 10.1016/S0030-6665(02)00167-6 * |
SHEMESH Z. ET AL: "Vitamin B12 Deficiency in Patients With Chronic-Tinnitus and Noise-Induced Hearing Loss", AMERICAN JOURNAL OF OTOLARYNGOLOGY, vol. 14, no. 2, March 1993 (1993-03-01), pages 94 - 99, XP022898969 * |
Also Published As
Publication number | Publication date |
---|---|
WO2007104566A1 (de) | 2007-09-20 |
EA200801890A1 (ru) | 2009-04-28 |
EA013457B1 (ru) | 2010-04-30 |
AU2007224668A1 (en) | 2007-09-20 |
US20090220592A1 (en) | 2009-09-03 |
IL194066A0 (en) | 2009-09-22 |
DE102006011922A1 (de) | 2007-09-20 |
CA2646528A1 (en) | 2007-09-20 |
US20110280972A1 (en) | 2011-11-17 |
JP2009529559A (ja) | 2009-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Brinkeborn et al. | Echinaforce® and other Echinacea fresh plant preparations in the treatment of the common cold: a randomized, placebo controlled, double-blind clinical trial | |
DE60208216T2 (de) | Verfahren zur behandlung von mittelohrinfektionen | |
WO1995017889A1 (fr) | Composition therapeutique utile pour traiter l'hyperparathyroidie d'un patient en dialyse artificielle | |
EP1993578A1 (de) | Mittel zur behandlung von tinnitus | |
DE69821524T2 (de) | Verwendung von vitis vinifera extrakten phospholipid komplexen als antiatherosclerotische mitteln | |
WO2009036906A1 (de) | Zusammensetzung mit wirkstoffkombination aus einem laxans und einem entschäumer zur behandlung von obstipation | |
EP2688577B1 (de) | Zusammensetzung zur anwendung bei verdauungsbeschwerden | |
WO2005092330A1 (de) | Arzneimittel oder diätetikum zur oralen verabreichung enthaltend blaubeerextrakt sowie antioxidatien und mikronährstoffe | |
US20090274780A1 (en) | Menopause treatment composition and regimen | |
DE3116859A1 (de) | Therapeutische zubereitungen fuer die behandlung einer tardiven dyskinesie | |
DE202004006157U1 (de) | Arzneimittel bzw. Nahrungsergänzungsmittel | |
US11911431B2 (en) | Sustained release ashwagandha extract | |
EP4248955A2 (de) | Verfahren zur herstellung von leicht einzunehmenden tabletten mit trockenextrakt aus ginkgo biloba blättern | |
CN109350660A (zh) | 一种润肠通便的复方制剂及其制备方法 | |
CN108014237A (zh) | 一种治疗骨裂或骨折的药物组合物及其制备方法和用途 | |
CN114617916A (zh) | 一种枇杷叶提取物及其在康养方面中的应用 | |
DE202014005450U1 (de) | Lactosefreies Arzneimittel | |
CN108159236A (zh) | 一种治疗骨裂或骨折的药物组合物及其制备方法和用途 | |
EP2355815B1 (de) | Verwendung von leukotrien-inhibitoren zur behandlung von lungenerkrankungen bei frühgeborenen kindern | |
DE102008033254B4 (de) | Verfahren zur Herstellung eines einphasischen pharmazeutischen Präparates zur oralen Therapie der Regulierung des Blutdruckes | |
Wiesenauer et al. | New approaches to treating pollenosis—a pilot study | |
DE2922478A1 (de) | Arzneimittel zur behandlung von kreislauferkrankungen | |
CN117180439A (zh) | 治疗出血性疾病的化合物及其组合物 | |
CN108014236A (zh) | 一种治疗骨裂或骨折的药物组合物及其制备方法和用途 | |
DE102011111944A1 (de) | Verwendung von Diclofenac zur Verhinderung und Behandlung grippaler Infekte sowie durch grippale Infekte bewirkter Krankheitssymtome |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20080821 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA HR MK RS |
|
17Q | First examination report despatched |
Effective date: 20090326 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R003 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
18R | Application refused |
Effective date: 20181209 |